Jolkinolide B Mitigates Cerebral Ischemia–Reperfusion Injury by Promoting Microglial M1 / M2 Polarization Through the JAK2 / STAT3 Signaling Pathway
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70653 ↗At a glance
Journal article in CNS Neuroscience & Therapeutics, 2025. Written by Yupeng Guo and 5 co-authors. Institution: Department of Neurosurgery, Aviation General Hospital, Beijing, China. Major MEDLINE topics: Janus Kinase 2, Reperfusion Injury, Microglia, STAT3 Transcription Factor. Cited 9 times so far (Crossref); 59 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Microglia polarization and inflammatory response are closely related to cerebral ischemia–reperfusion injury (CIRI). The diterpenoid compound Jolkinolide B (JB) possesses anti‐inflammatory properties, but the effects of JB and the mechanism on CIRI remain unclear.
Methods
An middle cerebral artery occlusion/reperfusion (MCAO/R) rat model and an oxygen–glucose deprivation/reoxygenation (OGD/R)‐induced HAPI cell model were used to evaluate the neuroprotective effects and mechanisms of JB. Neurological deficits and histopathological changes were assessed using Longa scoring, corner turn tests, TTC, HE, Nissl, and TUNEL staining. ELISA, flow cytometry, Western blot, and immunofluorescence were employed to analyze pro‐inflammatory cytokines, JAK2/STAT3 pathway proteins, and microglial polarization. In vitro, JB's effects on cell viability and apoptosis were evaluated using CCK‐8 and LDH release assays. Validation experiments were conducted using the JAK2‐specific inhibitor WP1066 and activator Broussonin E.
Results
JB exhibited dose‐dependent neuroprotective effects in MCAO/R rats, improving neurological function, reducing infarction area, neuronal apoptosis, cerebral edema, and neuroinflammation. JB suppressed JAK2/STAT3 signaling by downregulating p‐JAK2, p‐STAT3, and M1 markers (iNOS, CD16) while upregulating M2 markers (Arg‐1, CD206) and reducing pro‐inflammatory cytokines (IL‐1β, TNF‐α, IFN‐γ). Both in vivo and in vitro, JB inhibited the JAK2/STAT3 signaling pathway and promoted microglial polarization from M1 to M2, alleviating CIRI. In vitro, JB enhanced HAPI cell viability, decreased apoptosis, and reduced LDH leakage.
Conclusion
The ability of JB to modulate microglial polarization through JAK2/STAT3 inhibition presents a promising pharmacological approach for cerebral ischemia–reperfusion injury management in stroke therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurosurgery, Aviation General Hospital, Beijing, China.
- Neurosurgical Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
ORCID profiles: Yupeng Guo, Shewei Guo
Cite
APA
Guo, Y., Dong, X., Liu, M., Liu, D., Wang, J., & Guo, S. (2025). Jolkinolide B Mitigates Cerebral Ischemia–Reperfusion Injury by Promoting Microglial M1 / M2 Polarization Through the JAK2 / STAT3 Signaling Pathway. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70653
Vancouver
Guo Y, Dong X, Liu M, Liu D, Wang J, Guo S. Jolkinolide B Mitigates Cerebral Ischemia–Reperfusion Injury by Promoting Microglial M1 / M2 Polarization Through the JAK2 / STAT3 Signaling Pathway. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70653
BibTeX
@article{Guo2025,
author = {Guo, Yupeng and Dong, Xuanwei and Liu, Min and Liu, Dongsheng and Wang, Jianxin and Guo, Shewei},
title = {Jolkinolide B Mitigates Cerebral Ischemia–Reperfusion Injury by Promoting Microglial M1 / M2 Polarization Through the JAK2 / STAT3 Signaling Pathway},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70653}
}
EUVIMED